Evidence map›Paper›PMID 26973117›Full record

ArticleNeurobiology of aging2016

β-amyloid, hippocampal atrophy and their relation to longitudinal brain change in cognitively normal individuals.

Evan Fletcher, Sylvia Villeneuve, Pauline Maillard, Danielle Harvey, Bruce Reed, William Jagust, Charles DeCarli

Abstract read
In one paragraph

Article in Neurobiology of aging, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Insulin resistance is associated with lower arterial blood flow and reduced cortical perfusion in cognitively asymptomatic middle-aged adults.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2017 · on this map
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Evan FletcherDepartment of Neurology, University of California at Davis, Davis, CA, USA. Electronic address: evanfletcher@gmail.com.
Sylvia VilleneuveDouglas Mental Health University Institute, McGill University, Montreal, Canada.
Pauline MaillardDepartment of Neurology, University of California at Davis, Davis, CA, USA.
Danielle HarveyDivision of Biostatistics, School of Medicine, University of California at Davis, Davis, CA, USA.
Bruce ReedDepartment of Neurology, University of California at Davis, Davis, CA, USA.
William JagustHelen Wills Neuroscience Institute, University of California, Berkeley, Berkeley CA, USA.
Charles DeCarliDepartment of Neurology, University of California at Davis, Davis, CA, USA.

Funding

UC Davis Alzheimer's Disease Core CenterP30AG010129 · NIA · UNIVERSITY OF CALIFORNIA DAVIS · PI DECARLI, CHARLES · 1991 to 2020
$28.3M
Temporal Trends, Novel Imaging and Molecular Characterization of Preclinical and Clinical Alzheimer's Disease in the Framingham CohortsR01AG054076 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI DECARLI, CHARLES, SESHADRI, SUDHA · 2016 to 2020
$12.3M
Heterogeneity of Mild Cognitive Impairment(MCI)R01AG021028 · NIA · UNIVERSITY OF CALIFORNIA DAVIS · PI DECARLI, CHARLES · 2003 to 2014
$4.6M
NRF2 Anti-Oxidant Systems and White Matter HyperintensitiesR01AG042292 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DECARLI, CHARLES, SHARP, FRANK R · 2013 to 2017
$3.0M
The impact of non-amyloid processes on cognitive agingR01AG047827 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DECARLI, CHARLES · 2014 to 2018
$2.9M
NIA NIH HHS P30 AG010129NIA NIH HHS P30 AG10129NIA NIH HHS R01 AG021028NIA NIH HHS R01 AG042292NIA NIH HHS R01 AG047827NIA NIH HHS R01 AG054076
6 · The paper itself

Abstract

Recent literature has examined baseline hippocampal volume and extent of brain amyloidosis to test potential synergistic effects on worsening cognition and extent of brain atrophy. Use of hippocampal volume in prior studies was based on the notion that limbic circuit degeneration is an early manifestation of the Alzheimer's Disease (AD) pathophysiology. To clarify these interactions early in the AD process, we tested the effects of amyloid and baseline normalized hippocampal volume on longitudinal brain atrophy rates in a group of cognitively normal individuals. Results showed that the combination of elevated β-amyloid and baseline hippocampal atrophy is associated with increased rates specific to the limbic circuit and splenium. Importantly, this atrophy pattern emerged from a voxelwise analysis, corroborated by regression models over region of interests in native space. The results are broadly consistent with previous studies of the effects of amyloid and baseline hippocampal atrophy in normals, while pointing to accelerated atrophy of AD-vulnerable regions detectable at the preclinical stage.

Indexed as

CognitionAgedAged, 80 and overAlzheimer DiseaseAmyloid beta-PeptidesAtrophyCerebral Amyloid AngiopathyCohort StudiesFemaleHippocampusHumansMagnetic Resonance ImagingMaleRegression AnalysisAmyloid beta-PeptidesAlzheimer'sAtrophyLongitudinalNeurodegenerationNormalsβ-amyloid

Identifiers

PMID26973117
PMCPMC4792128

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.